Devyser Diagnostics AB (publ) (STO:DVYSR)

Market Cap	1.74B
Revenue (ttm)	242.70M
Net Income (ttm)	-25.20M
Shares Out	16.65M
EPS (ttm)	-1.53
PE Ratio	n/a
Forward PE	57.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,869
Average Volume	9,352
Open	107.80
Previous Close	104.40
Day's Range	103.00 - 107.80
52-Week Range	83.30 - 159.60
Beta	0.74
RSI	38.98
Earnings Date	Feb 12, 2026

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analys...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 121
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DVYSR

Financial Performance

In 2024, Devyser Diagnostics AB's revenue was 216.90 million, an increase of 28.12% compared to the previous year's 169.30 million. Losses were -61.50 million, 14.7% more than in 2023.